Novartis Restructure Sees Drug Development And Oncology Chiefs Exit

Aims To Boost R&D And Commercial Performance

 
• By Andrew McConaghie
  
Novartis_Building
Novartis aims to save $1bn over the next few years, and find more transformational new medicines from inside and outside its own R&D operations. • Source: Getty Images
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category